NeuroTau, Inc. is a biotech company, formed in 2017, that focuses on developing drugs that target the disruption or decay of the important neurobiological protein called Tau, and other important and associated proteins like amyloid and processes to reduce harmful inflammation that can lead to many serious diseases with significant unmet medical needs.
Our development programs are primarily focused on neurodegenerative & neuromuscular diseases including: Progressive Supranuclear Palsy, Frontotemporal Dementia, Alzheimer’s Disease, Traumatic Brain Injury, PTSD, Down’s syndrome, and Parkinson Disease.
On-going research has linked these diseases to various malfunctions of tau, amyloid and inflammation within the brain. By correcting them, NeuroTau aims at opening the way for a broad range of disease modifying mechanism-based therapies.
NeuroTau is led by a team of scientific, clinical and industry executives with over 75-years of combined experience and a passion to bring forward breakthrough drug therapies for a host of brain-related diseases.
Company Details
- Founded
- -
- Address
- Warwick, Ri 02886, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://neurotau.com/
- HQ
- Warwick, RI
- Competitors
- NMD Pharma A/S.
Neurotau, Inc. Questions
Neurotau, Inc.'s website is http://neurotau.com/
Neurotau, Inc.'s LinkedIn profile is https://www.linkedin.com/company/neurotau
Neurotau, Inc.'s industry is
Biotechnology Research
Neurotau, Inc.'s top competitors are
Nmd Pharma A/s.
Neurotau, Inc.'s categories are Biotechnology Research
Neurotau, Inc.'s founding year is 2017
